Indivior Expects FY23 Net Revenue Of $1.03B-$1.09B Vs. Consensus Of $1.05B; Adjusted Gross Margin Of Low Mid 80% Range; Adjusted Operating Income Of $212M
Author: Benzinga Newsdesk | November 09, 2023 04:27am
Updated (November 9, 2023) July 27, 2023 Net Revenue (NR)1 No change $1,030m to $1,090m (+18% vs. FY 2022 at the mid-point) SUBLOCADE NR $610m to $630m (+52% vs. FY 2022 at the mid-point) $590m to $630m (+50% vs. FY 2022 at the mid-point) PERSERIS NR Lower end of $45m to $55m $45m to $55m (+79% vs. FY 2022 at the mid-point) SUBOXONE Film Market Share Accelerated rate of share decline in Q4 20232, including the impact from the launch of a fourth buprenorphine/naloxone sublingual film generic in the U.S. market Accelerated rate of share decline in Q4 20232, including the assumed impact from the launch of a fourth buprenorphine/ naloxone sublingual film generic entering the U.S. market in early Q4 2023 Adjusted Gross Margin No change Low to mid 80% range Adjusted SG&A $540m to $550m (+$10m) $530m to $540m R&D No change $90m to $100m Adjusted Operating Profit No change Higher than FY 2022’s adjusted operating income of $212m, as a result of higher NR guidance
Posted In: INDV